FindTrial
Sign In

Effect of height on ED50 ED95 of intrathecal ropivacaine in pregnant patients undergoing cerean delivery

Effect of height on ED50 ED95 of intrathecal ropivacaine in pregnant patients undergoing cerean delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-13003108
Enrollment
Unknown
Registered
2013-03-20
Start date
2013-03-25
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnant patients undergoing cerean delivery

Interventions

Low height group (160cm):intrathecal ropivacaine

Sponsors

Guangzhou Women Children Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: ASA I, II; singleton pregnancy; aged between 18 to 40 yr; gestational age of more than 37 completedweeks undergoing elective cerean delivery; Less than two previous cerean deliveries

Exclusion criteria

Exclusion criteria: significant medical or obstetric morbidity; placenta previa, congenital anomaly; excluded if they have cardiorespiratory, renal or hepatic dysfunction. if they receive medications known to affect anesthetic requirements or allergy

Design outcomes

Primary

MeasureTime frame
ED50 and ED95 of intrathecal ropivacain;—

Secondary

MeasureTime frame
the rate of hypotension;—

Countries

China

Contacts

Public ContactSong Xing Rong
songxr1966@sohu.com+86 13922416303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026